IP Library › Granted Patent US 12,371,404
Granted Patent B2
US 12,371,404 · App. 18/384,197 · Granted Jul 29, 2025

Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy

Inventors: Kenneth Batchelor (Wilmington, NC); Jeffery E. Cobb (Chapel Hill, NC); Kristjan S. Gudmundsson (Raleigh, NC); Brad R. Henke (Cary, NC); Francis X. Tavares (Durham, NC)
Assignee: NovaTarg, Inc.
C07D209/20A61P3/10C07D209/32C07D471/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,371,404
App. No.
18/384,197
Granted
Jul 29, 2025
Kind
B2
Abstract

The present invention provides novel fused bicyclic alkylene linked imidodicarbonimidic diamides. In particular, described herein are N-[2-(indol-3-yl)alkylene]-linked imidodicarbonimidic diamides and N-[2-(pyrrolopyridin-3-yl)alkylene]-linked imidodicarbonimidic diamides (compound of formula (I) or formula (II)), and uses therefor. The compounds of the present invention are believed to be organic cation transporter selective compounds, useful for the treatment of diseases and conditions caused by reduced activity of 5′ adenosine monophosphate-activated protein kinase (AMPK).

Claims (2)

1. A compound of formula:

or a pharmaceutically acceptable salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2023
From: BATCHELOR, KENNETH; COBB, JEFFERY E.; GUDMUNDSSON, KRISTJAN S.; HENKE, BRAD R.; TAVARES, FRANCIS X.
To: NOVATARG, INC.
Reel/Frame 065379/0192 →
Continuity (5)
Continuation 17578050 · Jan 18, 2022
Division 16467136
Provisional Application 62454147 · Feb 3, 2017
Provisional Application 62431475 · Dec 8, 2016
Related Publication 20240327350A1 · Oct 3, 2024
References Cited (20)
US 3152181A · Shapiro et al. · 1964 [cited by applicant]
US 5322858A · Canfield et al. · 1994 [cited by applicant]
US 6169107B1 · Kitano et al. · 2001 [cited by applicant]
US 8796338B2 · Baron et al. · 2014 [cited by applicant]
US 11261157B2 · Batchelor · 2022 [cited by examiner]
US 11834411B2 · Batchelor · 2023 [cited by examiner]
US 20120283299A1 · Kim et al. · 2012 [cited by applicant]
WO 2015160220A1 · 2015 [cited by applicant]
Bartlett “Exploiting Chemical Diversity for Drug Discovery” Edited by Paul A Bartlett and Michael Entzeroth, The Royal Society of Chemistry, 2006, pp. 113-118. [cited by examiner]
“Find ETDs Home » Thesis Resources » Find ETDs” Online: “https://ndltd.org/thesis-resources/find-etds/” Accessed Jan. 31, 2023. [cited by examiner]
Irwin “Zinc—A Free Database of Commercially Available Compounds for Virtual Screening” J. Chem. Inf. Model. 2005, 45, 177-182. [cited by examiner]
Kim “PubChem in 2021: new data content and improved web interfaces” Nucleic Acids Research, 2021, vol. 49, Database issue Published online Nov. 5, 2020. [cited by examiner]
STN Registry/Zregistry (CAS Registrysm) Sep. 2016 2 pages. [cited by examiner]
Pubchem CID: 3373692, Create Date Jul. 7, 2005, pp. 1-14. [cited by applicant]
International Search Report, International Application No. PCT/US17/65095 filed Dec. 7, 2017, mailed Feb. 22, 2018. [cited by applicant]
West (West, Solid State Chemistry and Its Applications, John Wiley & Sons, 1984). [cited by applicant]
Pletnev, Khimiko-Famatsevticheskii Zhurnal (1972), 6(3), 27-9. [cited by applicant]
Hardie, “AMPK: Positive and Negative Regulation, and its Role in Whole-Body Energy Homeostasis”, Current Opinion in Cell Biology, 2015, 33:1-7. [cited by applicant]
Hardie et al., “AMPK: An Energy-Sensing Pathway with Multiple Inputs and Outputs”, Trends in Cell Biology, Mar. 2016, vol. 26, No. 3, 190-201. [cited by applicant]
Rabinovitch et al., “AMPK Maintains Celllular Metabolic Homeostasis through Regulation of Mitochondrial Reactive Oxygen Species”, Cell Reports 21, 1-9, Oct. 3, 2017. [cited by applicant]